Objective Measures of Nerve Integrity, Posture, Gait and Blood Flow, After Nerve Decompression (OMNIFICENT)
Objective Measures of Nerve Integrity, Posture, Gait and Blood Flow, After Nerve Decompression In diabetiC Neuropathy PatiENTs
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Megan L Fritz, D.C., M.S.
- Phone Number: 479-531-6133
- Email: megan.fritz.dc@gmail.com
Study Contact Backup
- Name: James C Anderson, DPM
- Phone Number: 970-484-4620
- Email: janderson@andersonpodiatrycenter.com
Study Locations
-
-
Colorado
-
Fort Collins, Colorado, United States, 80524
- Recruiting
- Anderson Podiatry Center, Neuropathy Testing Center of Colorado
-
Contact:
- Megan L Fritz, D.C., M.S.
- Phone Number: 479-531-6133
- Email: megan.fritz.dc@gmail.com
-
Contact:
- James C. Anderson, DPM
- Phone Number: 970-484-4620
- Email: janderson@andersonpodiatrycenter.com
-
Principal Investigator:
- James C. Anderson, DPM
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient has been diagnosed with diabetic peripheral neuropathy and has nerve deficit in all proposed surgical areas, sensory and/or motor
- Patient has a positive provocative (i.e. Tinel's sign) observed clinically in the popliteal and tibial nerve trees.
- Patient is between 18 years and 85 years of age
- Patient is a type I or type II diabetic that is currently under medical treatment
- Patient has a Hgb A1C lab value of 8.0% or less
- Patient symptom based VAS scale is 6 or above for at least one of the following: pain, burning, numbness, tingling, weakness or instability
- Patient is scheduled for surgery and has been cleared for outpatient surgery per anesthesia guidelines established for the Foot Surgery Center of Northern Colorado
- Patient is able and willing to comply with all study requirements, including the follow-up evaluations and will return to the investigational site for all required office visits and CSU visits
- Patient has been informed of the nature of the study, agrees to its provisions and has provided written consent
Exclusions Criteria:
- Patient has a BMI of greater than 40 or body weight greater than 300 pounds
- Patient has untreated hypertension (systolic blood pressure > 160 and/or diastolic > 100)
- Patient's ASA is 4 or greater
- Patient has blood glucose greater than 200 the day of surgery
- Patient has Raynaud's Syndrome
- Patient is a current smoker
- Patient is a woman who is considering pregnancy or who is pregnant
- Patient has history of recent nerve or lumbar disc surgery, untreated thyroid disease, B12 or Folate deficiency, hepatic disease, renal disease, and/or Parkinson's disease, or neuropathy due to chemotherapy or radiation therapy
- Patient is being treated with chemotherapeutic agents
- Patient has ankle edema greater than mild - (Moderate to Severe)
- Patient is participating in another investigational device, biologic, or drug study and has not completed the primary endpoint(s) or if there is a potential for clinical interference beyond the primary endpoint
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EMG signals used intraoperative as objective measurements of change before and after nerve decompression surgery. Gait, balance and blood flow measurements before and after peripheral nerve decompression surgery
Time Frame: Within one month of surgical date, surgical date, 3 months and 6 months post operative or 4 months postoperative if the subjects elect to have the contralateral limb surgery prior to 3 months following the initial surgery.
|
Primary Endpoint is assessed by changes in:
|
Within one month of surgical date, surgical date, 3 months and 6 months post operative or 4 months postoperative if the subjects elect to have the contralateral limb surgery prior to 3 months following the initial surgery.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in sensory perception
Time Frame: up to one month of surgical date, 3 months and 6 months post operative or 4 months postoperative if the subjects elect to have the contralateral limb surgery prior to 3 months following the initial surgery.
|
|
up to one month of surgical date, 3 months and 6 months post operative or 4 months postoperative if the subjects elect to have the contralateral limb surgery prior to 3 months following the initial surgery.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: James C. Anderson, DPM, Anderson Podiatry Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OMNI1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Peripheral Neuropathy
-
NCT07625007RecruitingDiabetic Peripheral Neuropathy
-
NCT07575113Not yet recruitingDiabetic Peripheral Neuropathy
-
NCT07380880Recruiting
-
NCT07260214Not yet recruitingDiabetic Peripheral Neuropathy
-
NCT07036796RecruitingDiabetic Peripheral Neuropathy | Diabetic Neuropathy | Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients
-
NCT07616661Active, not recruitingDiabetic Peripheral Neuropathy
-
NCT06544876RecruitingHealthy Aging | Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathy Type 2 | Diabetic Peripheral Neuropathy Type 2 - Uncontrolled
-
NCT07183761Recruiting
-
NCT07576179RecruitingDiabetic Peripheral Neuropathy (DPN)
-
NCT01247558CompletedDiabetic Peripheral Neuropathy (DPN)
Clinical Trials on Arm A - Non-Diabetic, Gait and Balance
-
NCT01158781CompletedTraumatic Brain Injury
-
NCT04981184Recruiting
-
NCT06617884RecruitingParkinson Disease | Ataxia
-
NCT06037044Active, not recruitingChildren With Acquired Brain Injury
-
NCT07653529Not yet recruitingIncomplete Spinal Cord Injury (SCI)
-
NCT05418569RecruitingType1 Diabetes Mellitus
-
NCT05090241CompletedFrail Elderly Syndrome | Fall Patients | Prevention | Geriatric Assessment
-
NCT04793594Not yet recruiting
-
NCT07368439Not yet recruitingChemotherapy Induced Peripheral Neuropathy (CIPN)